Novo Nordisk Denmark A/S - CVR: 38180045

2023, DKK

27.05.2024

Bruttoresultat

473''

Primær drift

101''

Årets resultat

81.998'

Aktiver

1.184''

Kortfristede aktiver

1.145''

Egenkapital

97.638'

Afkastningsgrad

9 %

Soliditetsgrad

8 %

Likviditetsgrad

113 %

Resultat

27.05.2024

Årsrapport	2023 27.05.2024	2022 16.06.2023	2021 17.05.2022	2020 15.06.2021	2019 03.06.2020	2018 24.05.2019	2016 03.05.2018
Nettoomsætning	2.017.346.469	509.919.862	373.940.044	330.145.351	363.935.809	341.939.236	317.442.873
Bruttoresultat	473.478.784	333.172.771	311.890.965	276.132.396	134.886.410	119.226.948	111.632.649
Resultat af primær drift	101.020.088	42.630.305	30.231.501	28.207.614	8.811.037	6.162.212	6.887.961
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0
Finansielle indtægter	9.715.586	2.356.913	474.522	822.093	398.140	421.608	564.250
Finansieringsomkostninger	-2.823.959	-952.921	-2.060.749	-1.021.898	-909.538	-335.098	-365.820
Andre finansielle omkostninger	0	0	0	0	0	0	0
Resultat før skat	107.911.715	44.034.297	28.645.274	28.007.809	8.299.639	6.248.722	7.086.391
Resultat	81.997.613	33.547.904	21.405.179	21.277.960	5.251.810	4.213.051	5.378.615
Forslag til udbytte	-82.000.000	-33.500.000	-21.400.000	-21.000.000	0	0	0

Aktiver

27.05.2024

Årsrapport	2023 27.05.2024	2022 16.06.2023	2021 17.05.2022	2020 15.06.2021	2019 03.06.2020	2018 24.05.2019	2016 03.05.2018
Kortfristede varebeholdninger	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	1.144.792.829	416.763.703	267.700.983	237.312.584	0	0	101.519.736
Likvider	0	0	0	326.474.370	137.161.043	29.448.964	21.595.659
Kortfristede aktiver	1.144.792.829	416.763.703	267.700.983	563.786.954	148.278.010	128.533.590	123.115.395
Immaterielle aktiver og goodwill	0	0	0	0	0	0	0
Finansielle anlægsaktiver	0	0	0	0	0	0	0
Materielle aktiver	39.211.206	29.970.121	15.719.412	21.184.481	1.329.741	1.506.592	1.683.443
Langfristede aktiver	39.211.206	29.970.121	15.719.412	21.184.481	1.329.741	1.506.592	1.683.443
Aktiver	1.184.004.035	446.733.824	283.420.395	584.971.435	149.607.751	130.040.182	124.798.838

Aktiver

27.05.2024

Passiver

27.05.2024

Årsrapport	2023 27.05.2024	2022 16.06.2023	2021 17.05.2022	2020 15.06.2021	2019 03.06.2020	2018 24.05.2019	2016 03.05.2018
Forslag til udbytte	82.000.000	33.500.000	21.400.000	21.000.000	0	0	0
Egenkapital	97.638.061	49.140.448	36.992.544	36.587.365	15.343.476	10.091.666	5.878.615
Hensatte forpligtelser	44.897.615	38.071.560	37.861.758	2.599.242	1.261.926	1.024.084	1.024.084
Langfristet gæld til banker	0	0	0	0	0	0	0
Anden langfristet gæld		0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	33.345.109	20.501.974	19.830.628	25.481.550	0	10.938.533	0
Kortfristede forpligtelser	1.011.586.791	338.908.822	203.802.037	526.876.317	133.002.349	118.924.432	0
Gældsforpligtelser	1.041.468.359	359.521.816	208.566.093	545.784.828	133.002.349	118.924.432	117.896.139
Forpligtelser	1.041.468.359	359.521.816	208.566.093	545.784.828	133.002.349	118.924.432	117.896.139
Passiver	1.184.004.035	446.733.824	283.420.395	584.971.435	149.607.751	130.040.182	124.798.838

Passiver

27.05.2024

Nøgletal

27.05.2024

Årsrapport	2023 27.05.2024	2022 16.06.2023	2021 17.05.2022	2020 15.06.2021	2019 03.06.2020	2018 24.05.2019	2016 03.05.2018
Afkastningsgrad	8,5 %	9,5 %	10,7 %	4,8 %	5,9 %	4,7 %	5,5 %
Dækningsgrad	23,5 %	65,3 %	83,4 %	83,6 %	37,1 %	34,9 %	35,2 %
Resultatgrad	4,1 %	6,6 %	5,7 %	6,4 %	1,4 %	1,2 %	1,7 %
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	84,0 %	68,3 %	57,9 %	58,2 %	34,2 %	41,7 %	91,5 %
Payout-ratio	100,0 %	99,9 %	100,0 %	98,7 %	Na.	Na.	Na.
Gældsdæknings-nøgletal	3.577,3 %	4.473,6 %	1.467,0 %	2.760,3 %	968,7 %	1.838,9 %	1.882,9 %
Soliditestgrad	8,2 %	11,0 %	13,1 %	6,3 %	10,3 %	7,8 %	4,7 %
Likviditetsgrad	113,2 %	123,0 %	131,4 %	107,0 %	111,5 %	108,1 %	Na.

Resultat

27.05.2024

Gæld

27.05.2024

Årsrapport

27.05.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 27.05.2024)

Information om virksomhedens regnskabsklasse:The annual report for Novo Nordisk Denmark A/S has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class C enterprises (large enterprises). The accounting policies are unchanged from last year, and the annual report is presented in DKK. According to section 96 (3) of the Danish Financial Statements Act, the company has not disclosed the fee to the auditor, as the relevant information is included in the consolidated Financial Statements of Novo Nordisk A/S.

Beretning

27.05.2024

Dato for ledelsens godkendelse af årsrapporten:2024-05-21

Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Unusual matters having affected the financial statements No unusual matters has effected the financial statements for 2023.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Managing Director have approved the annual report of Novo Nordisk Denmark A/S for the financial year 1 January - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Business review Novo Nordisk Denmark A/S (secondary name Novo Nordisk Region Europe Pharmaceuticals A/S and Novo Nordisk North West Europe Pharmaceuticals A/S) is selling medicine in the treatment areas diabetes, obesity, rare endocrine and blood disorders as well as hormone replacement treatment. The company is located in Ørestad in Copenhagen, Denmark. Number of average employees has increased from 200 in 2022 to 236 in 2023. Novo Nordisk Denmark A/S consist of the following three business units: The Danish sales affiliate The unit is a fully operational sales affiliate with focus on the distribution of the medicine produced by Novo Nordisk A/S and Novo Nordisk Healthcare AG to patients in Denmark and Iceland. Novo Nordisk A/S and Novo Nordisk Healthcare AG bears all the risks for launches as well as research and development, hence launch costs and R&D costs are invoiced to Novo Nordisk A/S and Novo Nordisk Healthcare AG as service fee including a mark-up for internal costs. North West Europe regional office Service company supporting the business areas/large affiliates in Europe such as UK, France, Spain, Switzerland, Netherlands, Denmark, Sweden and business area North West Europe mid-size (Norway, Finland, Belgium, Austria, Portugal and Ireland). All costs, both internal and external are invoiced to Novo Nordisk A/S as service fee including a mark-up for internal costs. North West Europe mid size business area office Service company supporting the affiliates in business area North West Europe mid-size (Norway, Finland, Belgium, Austria, Portugal and Ireland). All costs, both internal and external are invoiced to the affiliates in business area NWE mid-size and to Novo Nordisk A/S. All costs, both internal and external are invoiced to Novo Nordisk A/S as service fee including a mark-up for internal costs.